306 related articles for article (PubMed ID: 33106104)
1. Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
DiSogra KY; Tran T; Arnall JR; Janes A; Moore DC; Park SI
J Oncol Pharm Pract; 2021 Jul; 27(5):1265-1269. PubMed ID: 33106104
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review.
Ghasoub R; Albattah A; Elazzazy S; Alokka R; Nemir A; Alhijji I; Taha R
J Oncol Pharm Pract; 2020 Mar; 26(2):487-491. PubMed ID: 31216242
[TBL] [Abstract][Full Text] [Related]
3. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
4. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
5. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
Barrientos JC; Burger JA; Byrd JC; Hillmen P; Zhou C; Ninomoto J; James DF; Kipps TJ
Leuk Lymphoma; 2019 Apr; 60(4):1000-1005. PubMed ID: 30277101
[TBL] [Abstract][Full Text] [Related]
6. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib in B lymphoid malignancies.
Smith MR
Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
[TBL] [Abstract][Full Text] [Related]
9. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N
J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204
[TBL] [Abstract][Full Text] [Related]
10. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
Gayko U; Fung M; Clow F; Sun S; Faust E; Price S; James D; Doyle M; Bari S; Zhuang SH
Ann N Y Acad Sci; 2015 Nov; 1358():82-94. PubMed ID: 26348626
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Titus-Rains KS; Brown JN; Hammond JM
J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377
[TBL] [Abstract][Full Text] [Related]
12. Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib.
Lasica M; Tam CS
Hematol Oncol Clin North Am; 2021 Aug; 35(4):761-773. PubMed ID: 34174985
[TBL] [Abstract][Full Text] [Related]
13. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
14. Bruton's tyrosine kinase inhibitors and the kidney: Focus on ibrutinib.
Brener ZZ; Brener H; Losev A
J Oncol Pharm Pract; 2020 Oct; 26(7):1735-1737. PubMed ID: 32054411
[TBL] [Abstract][Full Text] [Related]
15. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib dose modifications in the management of CLL.
Hardy-Abeloos C; Pinotti R; Gabrilove J
J Hematol Oncol; 2020 Jun; 13(1):66. PubMed ID: 32503582
[TBL] [Abstract][Full Text] [Related]
17. Metabolic and toxicological considerations of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Wolska-Washer A; Robak P; Witkowska M; Robak T
Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):207-224. PubMed ID: 38516702
[TBL] [Abstract][Full Text] [Related]
18. Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib.
Gülsaran SK; Baysal M; Demirci U; Baş V; Kirkizlar HO; Umit E; Demir AM
J Oncol Pharm Pract; 2020 Mar; 26(2):478-480. PubMed ID: 31142233
[TBL] [Abstract][Full Text] [Related]
19. Screening and monitoring of the BTK
Bödör C; Kotmayer L; László T; Takács F; Barna G; Kiss R; Sebestyén E; Nagy T; Hegyi LL; Mikala G; Fekete S; Farkas P; Balogh A; Masszi T; Demeter J; Weisinger J; Alizadeh H; Kajtár B; Kohl Z; Szász R; Gergely L; Gurbity Pálfi T; Sulák A; Kollár B; Egyed M; Plander M; Rejtő L; Szerafin L; Ilonczai P; Tamáska P; Pettendi P; Lévai D; Schneider T; Sebestyén A; Csermely P; Matolcsy A; Mátrai Z; Alpár D
Br J Haematol; 2021 Jul; 194(2):355-364. PubMed ID: 34019713
[TBL] [Abstract][Full Text] [Related]
20. [Ibrutinib prescription in B-cell lymphoid neoplasms].
Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
